MDxHealth SA (MXDHF) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of MDxHealth SA (OTCMKTS:MXDHF) from a buy rating to a hold rating in a report issued on Saturday.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “

Shares of MDxHealth SA (OTCMKTS:MXDHF) opened at $4.31 on Friday. MDxHealth SA has a 52 week low of $4.26 and a 52 week high of $6.15.

TRADEMARK VIOLATION NOTICE: “MDxHealth SA (MXDHF) Rating Lowered to Hold at Zacks Investment Research” was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/15/mdxhealth-sa-mxdhf-rating-lowered-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on MDxHealth SA (MXDHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MDxHealth SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply